• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Celldex Therapeutics (NQ: CLDX )

    27.63 +2.20 (+8.65%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,718,447
    Open 26.00
    Bid (Size) 26.63 (1)
    Ask (Size) 29.11 (1)
    Prev. Close 25.43
    Today's Range 24.87 - 28.11
    52wk Range 24.43 - 53.18
    Shares Outstanding 66,344,236
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Analyst Expectations For Celldex Therapeutics's Future
    Via Benzinga
    Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -31.63%
    -31.63%
    1 Month
    -9.14%
    -9.14%
    3 Month
    -13.82%
    -13.82%
    6 Month
    -32.95%
    -32.95%
    1 Year
    -4.79%
    -4.79%

    More News

    Read More
    Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics
    Via Benzinga
    The Analyst Verdict: Celldex Therapeutics In The Eyes Of 7 Experts
    Via Benzinga
    7 Analysts Have This To Say About Celldex Therapeutics
    Via Benzinga
    This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
    Via Benzinga
    Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Analyst Expectations For Celldex Therapeutics's Future
    Via Benzinga
    Analyst Expectations For Celldex Therapeutics's Future
    Via Benzinga
    Unveiling 4 Analyst Insights On Celldex Therapeutics
    Via Benzinga
    Celldex Therapeutics to Present at Upcoming Investor Conferences
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
    Via Benzinga
    Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Celldex Therapeutics to Present at Jefferies Healthcare Conference
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.